Mysoline: Effective Seizure Control for Epilepsy Management
| Product dosage: 250 mg | |||
|---|---|---|---|
| Package (num) | Per tab | Price | Buy |
| 30 | $1.37 | $41.17 (0%) | 🛒 Add to cart |
| 60 | $1.07 | $82.33 $64.26 (22%) | 🛒 Add to cart |
| 90 | $1.02 | $123.50 $91.37 (26%) | 🛒 Add to cart |
| 120 | $0.92 | $164.67 $110.45 (33%) | 🛒 Add to cart |
| 180 | $0.86 | $247.00 $155.63 (37%) | 🛒 Add to cart |
| 360 | $0.77
Best per tab | $494.00 $276.12 (44%) | 🛒 Add to cart |
Synonyms | |||
Mysoline (primidone) is an established anticonvulsant medication specifically formulated for the management of seizure disorders. As a barbiturate derivative, it exerts its therapeutic effects by reducing abnormal electrical activity in the brain, thereby stabilizing neuronal membranes and raising the seizure threshold. This medication has demonstrated particular efficacy in treating grand mal, psychomotor, and focal epileptic seizures, offering patients a proven option for long-term seizure management. Clinical evidence supports its use both as monotherapy and as part of combination treatment regimens under appropriate neurological supervision.
Features
- Contains primidone as the active pharmaceutical ingredient
- Available in 50 mg and 250 mg scored tablets for precise dosing
- Demonstrated efficacy across multiple seizure types
- Established pharmacokinetic profile with predictable absorption
- Manufactured under strict quality control standards
- Compatible with various antiepileptic drug monitoring protocols
Benefits
- Provides reliable reduction in seizure frequency and intensity
- Enables improved daily functioning and quality of life for epilepsy patients
- Offers flexible dosing options tailored to individual therapeutic needs
- Supports long-term seizure management with established safety data
- May reduce emergency department visits and hospitalizations related to breakthrough seizures
- Facilitates better sleep patterns in patients with nocturnal seizure activity
Common use
Mysoline is primarily indicated for the control of grand mal, psychomotor, and focal epileptic seizures. It may be used as either monotherapy or adjunctive therapy in patients with refractory epilepsy. Neurologists may also prescribe Mysoline for essential tremor when first-line treatments prove insufficient. The medication requires careful titration and ongoing monitoring to achieve optimal therapeutic effects while minimizing adverse reactions.
Dosage and direction
Initial Adult Dosage: 100-125 mg at bedtime for the first three days
Titration Schedule: Increase by 100-125 mg every three days until therapeutic response achieved
Maintenance Range: 750-1500 mg daily in divided doses (3-4 times daily)
Maximum Daily Dose: 2000 mg (requires careful monitoring)
Geriatric Patients: Initiate with lower doses due to reduced clearance
Pediatric Patients (≥8 years): 50-125 mg daily initially, gradually increased to 10-25 mg/kg/day in divided doses
Take with food to minimize gastrointestinal discomfort. Tablets should be swallowed whole with water. Do not crush or chew extended-release formulations. Regular blood level monitoring is essential during dosage adjustments.
Precautions
- Regular monitoring of complete blood count and liver function tests required
- Caution advised in patients with respiratory depression or obstructive pulmonary disease
- Increased risk of suicidal thoughts and behaviors; monitor for mood changes
- May cause drowsiness; avoid driving or operating machinery until response established
- Use with caution in patients with renal or hepatic impairment
- Abrupt discontinuation may precipitate status epilepticus; taper gradually
- Pregnancy Category D: Weigh potential benefits against fetal risks
Contraindications
- Hypersensitivity to primidone or barbiturates
- Patients with porphyria
- Severe respiratory depression
- Significant hepatic impairment
- Concurrent use with monoamine oxidase inhibitors (MAOIs)
- History of drug abuse or dependence
Possible side effect
Common (≥1%): Drowsiness, dizziness, ataxia, nausea, vomiting, fatigue, nystagmus
Less Common (0.1-1%): Rash, megaloblastic anemia, osteomalacia, emotional disturbances
Rare (<0.1%): Stevens-Johnson syndrome, agranulocytosis, hepatic dysfunction
Neurological: Cognitive impairment, memory difficulties, confusion in elderly patients
Psychiatric: Depression, agitation, paradoxical excitement in children
Drug interaction
- Enhanced CNS Depression: Alcohol, benzodiazepines, opioids, sedating antihistamines
- Reduced Efficacy: Oral contraceptives, warfarin, corticosteroids, tricyclic antidepressants
- Metabolic Interactions: Valproic acid (increases primidone levels), carbamazepine (decreases levels)
- Enzyme Induction: Accelerates metabolism of numerous drugs including antiepileptics
- Serotonin Syndrome Risk: When combined with serotonergic agents
Missed dose
Take the missed dose as soon as remembered unless it is almost time for the next scheduled dose. Do not double the dose to make up for a missed administration. If multiple doses are missed, contact your healthcare provider for guidance on resumption, as dosage adjustment may be necessary. Maintain a consistent dosing schedule to ensure stable blood levels.
Overdose
Symptoms: Severe CNS depression, respiratory depression, hypotension, coma, hypothermia
Management: Immediate medical attention required. Gastric lavage if presented early. Supportive care including maintenance of airway, ventilation, and hemodynamic stability. Hemodialysis may be considered in severe cases. There is no specific antidote; treatment is symptomatic and supportive.
Storage
Store at room temperature (15-30°C/59-86°F) in original container. Protect from light and moisture. Keep tightly closed. Do not store in bathroom or near sink. Keep out of reach of children and pets. Do not use after expiration date printed on packaging.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before starting or changing any medication regimen. Individual response to therapy may vary. Proper diagnosis and monitoring by a physician are essential for safe and effective use of Mysoline.
Reviews
Clinical Perspective: “Mysoline remains a valuable option in our antiepileptic arsenal, particularly for patients who have failed first-line therapies. Its long-term efficacy data is robust, though careful monitoring is essential.” - Neurologist, 15 years experience
Patient Experience: “After struggling with uncontrolled seizures for years, Mysoline finally provided the stability I needed. The initial drowsiness was challenging but improved with dose adjustment.” - Patient, 4 years on therapy
Research Summary: Multiple studies demonstrate Mysoline’s effectiveness in reducing seizure frequency by 50% or more in approximately 60-70% of appropriately selected patients. Long-term studies show maintained efficacy with proper monitoring.